Eyevance Pharmaceuticals LLC.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eyevance Pharmaceuticals LLC.
Keeping Track: US FDA Clears Santen’s Omlonti, Fennec’s Pedmark; Lilly’s Retevmo Adds Tumor-Agnostic Claim
The latest drug approval news and highlights from the Pink Sheet’s US FDA Performance Tracker
Santen CEO's Clear Vision For World 'Built On Ability To See'
CEO of Japanese ophthalmology specialist lays out clear-sighted business vision as track laid for expansion into global markets and new indications amid expiry challenges at home. New modalities are also being explored to meet needs in demanding disorders, Shigeo Taniuchi tells Scrip in an exclusive interview.
Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Eyevance Pharmaceuticals, LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.